跳至主要内容
临床试验/EUCTR2008-007344-34-NL
EUCTR2008-007344-34-NL进行中(未招募)不适用

External Cephalic Version with uterine relaxation: atosiban versus fenoterol, a multi-centre trial - ECV: atosiban vs fenoterol

Academic Medical Centre0 个研究点开始时间: 2009年5月25日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • 1.Live singleton fetus
  • 2.Breech presentation
  • 3.Gestational age of 32 weeks and onwards
  • 4.Maternal age of 18 years or more
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Maternal exclusion criteria;
  • -Any contra-indications to labour or vaginal birth (eg placenta praevia)
  • -Any contra-indication to ECV:
  • - A scarred uterus other than transverse in the lower segment
  • - Known uterine anomalies
  • - Placental abruption in the obstetric history
  • - Preeclampsia or eclampsia
  • - Third trimester blood loss
  • - Ruptured membranes
  • -Any contra-indication to atosiban or fenoterol:
  • - Cardiovascular disease
  • - Hyperthyreoidism
  • - Elevated liver enzymes or renal dysfunction
  • - Infection of the amniotic cavity
  • - Simultaneous use of prostaglandin inhibitors, beta-blockers (labetalol
  • (trandate)), xanthine derivatives (theofylline), tricyclic antidepressants,
  • calcium, vitamin D, mineralocorticoids.
  • - Use of prostaglandin inhibitors, beta-blockers (labetalol) tricyclic
  • antidepressants.
  • Fetal exclusion criteria;
  • -Suspected severe intrauterine growth restriction ( assessed by ultrasonography) or severe oligohydramnios (deepest pool <
  • -Fetal anomalies or an extended fetal head (very rare)
  • -Non reassuring signs of fetal well-being; non-reassuring fetal heart rate

研究者

发起方
Academic Medical Centre

相似试验